Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Dr Reddy's Rolls Out New Generic Ozempic Brands To Ease Obeda Supply Hit - Reuters
- Deckers Outdoor (DECK) PT Lowered to $100 at Williams Trading
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
